Biogen presents lupus data: Biogen stock loses 2.06 percent

Published on 10/08/2026 at 21:04 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Litifilimab reached 27.20 percent clear skin at week 52, up from 19.00 percent at week 24. Biogen stock costs EUR 194.17 versus EUR 198.25 on October 8, 2026.

Key points in brief

Biogen presented 52-week litifilimab data on October 2, 2026, with 27.20 percent of participants achieving clear or almost clear skin.
The response rate increased from 19.00 percent at week 24 to 27.20 percent at week 52 in the AMETHYST study.
Biogen stock was trading at EUR 194.17 at Lang & Schwarz on October 8, 2026, down 2.06 percent versus EUR 198.25.

Extreme Makro-Aufnahme einer biolumineszierenden Nervenzelle mit Myelinscheide vor schwarzem Hintergrund — Biogen Inc. Makroaufnahme einer leuchtenden Nervenzelle mit Myelinscheide für MS-Forschung ISIN US09062X1037, Illustration mit AI erstellt.

Biogen Inc. (ISIN US09062X1037) was trading at EUR 194.17 in after-hours trading at Lang & Schwarz on October 8, 2026, down 2.06 percent versus the prior close of EUR 198.25. On October 2, 2026, Biogen presented 52-week results for litifilimab in cutaneous lupus erythematosus, with 27.20 percent of participants achieving clear or almost clear skin, according to GlobeNewswire.

Three milestones reshape the pipeline

On July 29, 2026, Biogen reported second-quarter revenue of USD 2.74 billion against a USD 2.46 billion consensus, while revenue increased 3.40 percent from the prior year, according to MarketBeat.

On September 17, 2026, Biogen reported that EMPAVELI-treated adolescents achieved a 75.00 percent relative reduction in proteinuria versus placebo at week 26, according to Biogen.

On October 2, 2026, the litifilimab data showed the skin-clearance rate rising from 19.00 percent at week 24 to 27.20 percent at week 52. The same release said 28.80 percent of participants achieved at least a 70.00 percent reduction in disease activity at week 52, compared with 21.70 percent at week 24, according to GlobeNewswire.

What do the data mean for Biogen?

The clinical signal is material for a pipeline that remains in development. AMETHYST enrolled 93 adults, and the Phase 3 portion remains blinded; Biogen said the Phase 3 readout is expected in the first half of 2027, so the 52-week Phase 2 results do not establish regulatory approval.

The upcoming financial checkpoint is October 28, 2026, when Biogen plans to report third-quarter results before the market opens and host a webcast at 8:30 a.m. ET, according to Biogen. The first-half 2027 AMETHYST readout is the next major clinical date cited in the litifilimab release.

Biogen stock reflects a volatile session

Biogen stock was trading at EUR 194.17 at Lang & Schwarz on October 8, 2026, down 2.06 percent from the EUR 198.25 prior close. On the Nasdaq, the stock range over the past 52 weeks was USD 138.00 to USD 230.49, while market capitalization stood at USD 32.20 billion on October 8, 2026.

The further course of trading is shown by the continuously updated real-time quote of Biogen stock.